Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qixuetongzhi
- Development stage
- Unknown
- Lead developer
- Xiyuan Hospital
- Administration
- Oral
01
Overview
Qixuetongzhi is a Traditional Chinese Medicine (TCM) formula developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is primarily investigated for the treatment of stable coronary heart disease (CHD). The formula is designed to improve cardiopulmonary endurance, alleviate angina pectoris, and address comorbid anxiety and depression in CHD patients. Its therapeutic approach is rooted in TCM principles of regulating Qi and promoting blood circulation to resolve stagnation. Clinical evaluation focuses on its efficacy in improving patient prognosis and reducing long-term cardiovascular adverse events.
- Brand names
- Qixue Tongzhi Granule
- Other names
- Qixuetongzhi FormulaQixuetongzhi granule
Beyond the preview
Go deeper on Qixuetongzhi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qixuetongzhi.